Lasofoxifene Tartrate not checked

Azure Biotech Inc. · AZU-101

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total

What this is

How it works
How it works isn't classified yet
Tested for
Vulvo Vaginal Atrophy (VVA)
Main trialPhase 2
“Study Objectives: Primary: • To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: • To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium”In the company’s words, NCT06197568 on ClinicalTrials.gov
Other names
AZU-101

Other drugs for Vulvo Vaginal Atrophy (VVA)

All 2 drugs for Vulvo Vaginal Atrophy (VVA)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Dec 2026 Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Lasofoxifene Tartrate

Following is part of Solo: you see every change to Lasofoxifene Tartrate the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in